SUWANEE, Ga., Jan. 31, 2017 -- Digirad Corporation (NASDAQ:DRAD) today announced a quarterly cash dividend of $0.05 per share. The dividend is payable on February 28, 2017 to shareholders of record as of February 15, 2017.
About Digirad
Digirad delivers convenient, effective, and efficient healthcare solutions on an as needed, when needed, and where needed basis. Digirad’s diverse portfolio of mobile healthcare solutions and medical equipment and services, including diagnostic imaging and patient monitoring, provides hospitals, physician practices, and imaging centers throughout the United States access to technology and services necessary to provide exceptional patient care in the rapidly changing healthcare environment. For more information, please visit www.digirad.com.
Contact Information: Digirad Corporation — Investors Jeff Keyes Chief Financial Officer [email protected] 858-726-1600


Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Italy Fines Apple €98.6 Million Over App Store Dominance
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 



